Cadence Pharmaceuticals, Inc. (CADX) Posts Q4 Loss of 25c/Share; Guides FY13 Revs
Tweet Send to a Friend
Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) reported Q4 EPS of ($0.25), $0.09 worse than the analyst estimate of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
